Wir sind mit live! Mehr erfahren

Black Diamond Therapeutics

BDTX

Börsenwert 98,8 Mio. $

1,72 USD

-0,02

1,15 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

1,71

-0,01

0,58 %

1 Tag

-1,15 %

5 Tage

-8,02 %

1 Monat

-11,34 %

3 Monate

-4,97 %

6 Monate

-41,1 %

Seit Jahresbeginn

-30,92 %

1 Jahr

-58,85 %

5 Jahre

-77,75 %

10 Jahre

-95,64 %

Profil: Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Mitarbeiter: 21

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 33,3 %

Neutral 66,7 %

Negativ 0 %

Zacks Investment Research

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D.

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Zacks Investment Research

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Zacks Investment Research

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

Zacks Investment Research

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Zacks Investment Research

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt